Table 1.
Patient characteristics at diagnosis
| Characteristic | Number (%) |
|---|---|
| Sex | |
| Male | 44 (63) |
| Female | 25 (37) |
| Age | |
| ≤ 60 years | 43 (62) |
| > 60 years | 26 (38) |
| Subtype | |
| PTCL, NOS | 28 (40) |
| ENKTL | 24 (35) |
| AITL | 8 (12) |
| ALCL ALK+/ALK- | 2/7 (13) |
| Stage | |
| I/II | 11/14 (36) |
| III/IV | 13/31 (64) |
| Serum LDH | |
| Normal | 29 (42) |
| Increased | 40 (58) |
| Number of involved extranodal lesion | |
| 0 | 7 (10) |
| 1 | 36 (52) |
| ≥ 2 | 26 (38) |
| IPI risk | |
| Low | 25 (36) |
| Low-Intermediate | 12 (17) |
| High-Intermediate | 21 (30) |
| High | 11 (16) |
| Bone marrow involvement | |
| Absent | 53 (77) |
| Present | 16 (23) |
| B symptoms | |
| Absent | 44 (64) |
| Present | 25 (36) |
PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified; ENKTL, extranodal NK/T-cell lymphoma; AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma kinase; LDH, lactate dehydrogenase; IPI, international prognostic index; BM, bone marrow